Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 360 results:
Συντάκτης Τίτλος Τύπος [ Έτος(Asc)]
Φίλτρα: Συντάκτης is Polyzos, Stergios A  [Clear All Filters]
2022
Kountouras, J., Papaefthymiou A., Polyzos S. A., Kyrailidi F., & Doulberis M. (2022).  Potential impact of Helicobacter pylori-related metabolic syndrome on arterial hypertension outcomes.. Am J Hypertens.
Polyzos, S. A., & Katsiki N. (2022).  Semaglutide, cilofexor, and firsocostat for nonalcoholic steatohepatitis: a dance that may need more than one dancer.. Hormones (Athens).
Kouvari, M., Polyzos S. A., Chrysohoou C., Skoumas J., Pitsavos C. S., Panagiotakos D. B., et al. (2022).  Skeletal muscle mass and abdominal obesity are independent predictors of hepatic steatosis and interact to predict ten-year cardiovascular disease incidence: Data from the ATTICA cohort study.. Clin Nutr. 41(6), 1281-1289.
2021
Boutari, C., Polyzos S. A., & Mantzoros C. S. (2021).  Addressing the epidemic of fatty liver disease: A call to action, a call to collaboration, a call to moving the field forward.. Metabolism. 122, 154781.
Polyzos, S. A., Tournis S., Goulas A., Kollia P., & Whyte M. P. (2021).  Adult hypophosphatasia treated with reduced frequency of teriparatide dosing.. J Musculoskelet Neuronal Interact. 21(4), 584-589.
Polyzos, S. A., Xanthopoulos K., & Kountouras J. (2021).  Cilofexor for the Treatment of Nonalcoholic Steatohepatitis. Curr Vasc Pharmacol.
Anastasilakis, A. D., Polyzos S. A., Yavropoulou M. P., Ntenti C., Mandanas S., & Makras P. (2021).  Circulating sclerostin levels during denosumab discontinuation and the subsequent early or late zoledronate infusion.. Endocrine.
Potoupni, V., Georgiadou M., Chatzigriva E., Polychronidou G., Markou E., Gakis C. Zapantis, et al. (2021).  Circulating tumor necrosis factor-α levels in non-alcoholic fatty liver disease: A systematic review and a meta-analysis.. J Gastroenterol Hepatol.
Anastasilakis, A. D., Polyzos S. A., Yavropoulou M. P., Appelman-Dijkstra N. M., Ntenti C., Mandanas S., et al. (2021).  Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation.. Calcif Tissue Int.
Polyzos, S. A., & Mantzoros C. S. (2021).  Diabetes mellitus: 100 years since the discovery of insulin.. Metabolism. 118, 154737.
Makras, P., Appelman-Dijkstra N. M., Papapoulos S. E., van Wissen S., Winter E. M., Polyzos S. A., et al. (2021).  The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation.. J Clin Endocrinol Metab.
Papaefthymiou, A., Doulberis M., Karafyllidou K., Chatzimichael E., Deretzi G., Exadaktylos A. K., et al. (2021).  Effect of spironolactone on pharmacological treatment of nonalcoholic fatty liver disease.. Minerva Endocrinol (Torino).
Anastasilakis, A. D., Polyzos S. A., Makras P., Trovas G., Yavropoulou M. P., & Tournis S. (2021).  Efficacy of Antiosteoporotic Medications in Patients With Rebound-Associated Fractures After Denosumab Discontinuation.. J Clin Densitom.
Makri, E., Goulas A., & Polyzos S. A. (2021).  Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease.. Arch Med Res. 52(1), 25-37.
Polyzos, S. A., Papaefthymiou A., Doulberis M., Mavridoglou G., & Kountouras J. (2021).  Helicobacter pylori infection and diabetes mellitus.. Diabetes Metab Syndr. 15(3), 845-846.
Doulberis, M., Pierre N. Thierry, Manzini G., Papaefthymiou A., Kountouras J., Klukowska-Rötzler J., et al. (2021).   Helicobacter pylori-Related Metabolic Parameters and Premalignant Gastric Mucosa Histological Lesions in Swiss Bariatric Patients.. Microorganisms. 9(7), 
Tournis, S., Yavropoulou M. P., Polyzos S. A., & Doulgeraki A. (2021).  Hypophosphatasia.. J Clin Med. 10(23), 
Kountouras, J., Papaefthymiou A., Doulberis M., Polyzos S. A., Zavos C., Kazakos E., et al. (2021).  Impact of Helicobacter pylori-related Metabolic Syndrome and Gastroesophageal Reflux Disease on the Risk of Acute Myocardial Infarction.. J Neurogastroenterol Motil. 27(1), 147-148.
Kountouras, J., Papaefthymiou A., Polyzos S. A., Deretzi G., Vardaka E., Soteriades E. S., et al. (2021).  Impact of -Related Metabolic Syndrome Parameters on Arterial Hypertension.. Microorganisms. 9(11), 
Kountouras, J., Papaefthymiou A., Polyzos S. A., Vardaka E., Boziki M., Kyriakopoulos A., et al. (2021).  Impact of -related Microbial Dysbiosis in the Pathogenesis of Metabolic Syndrome and Gastrointestinal Dysmotility Disorders.. J Neurogastroenterol Motil. 27(4), 653-654.
Papaefthymiou, A., Potamianos S., Goulas A., Doulberis M., Kountouras J., & Polyzos S. A. (2021).  Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents.. J Crohns Colitis.
Polyzos, S. A., Kountouras J., & Anastasilakis A. D. (2021).  Irisin in nonalcoholic fatty liver disease: Need for an updated meta-analysis.. Metabolism. 121, 154818.
Tessier, C. M., Polyzos S. A., Athyros V. G., & Mantzoros C. S. (2021).  Long-term statin treatment for hepatic fibrosis in patients with nonalcoholic fatty liver disease: Is it time to give the emperor a statin robe?. Metabolism. 121, 154796.
Sountoulides, P., Pyrgidis N., Polyzos S. A., Mykoniatis I., Asouhidou E., Papatsoris A., et al. (2021).  Micro-Ultrasound-guided Versus Multiparametric Magnetic Resonance Imaging-Targeted Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-Analysis.. J Urol. 101097JU0000000000001639.
Vachliotis, I., Goulas A., Papaioannidou P., & Polyzos S. A. (2021).  Nonalcoholic fatty liver disease: lifestyle and quality of life.. Hormones (Athens).

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές